Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate antiretroviral activity of up to five different oral
doses administered for two weeks of bevirimat versus placebo in HIV treatment experienced
patients, who have documented genotypic resistance to at least one major mutation from the
IAS-USA list (2007)of resistance mutations for NRTIs, NNRTIs, or PIs. Patients will also be
monitored for side effects, and the pharmacokinetics of bevirimat will be determined.